Konakion Mm Paediatric

Phytomenadione, the active ingredient in Konakion Mm Paediatric, is a Vitamin K presented as a paediatric formulation for intramuscular, intravenous, and oral use. It treats vitamin K deficiency, helps prevent hemorrhage in newborns, and reverses anticoagulant therapy in children. GNH USA supplies Konakion Mm Paediatric as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Konakion Mm Paediatric, a Vitamin K analogue, is used in conditions related to impaired coagulation.

- Vitamin K deficiency: restores normal clotting factor activity in deficient patients. - Prevention of hemorrhage in newborns: provides prophylactic vitamin K to reduce risk of neonatal bleeding. - Reversal of anticoagulant therapy: supplies vitamin K to counteract the effects of warfarin and other vitamin K antagonists.

Adverse reactions may occur with any route of administration.

Common Side Effects: - Injection site pain or erythema. - Mild fever or chills. - Nausea or vomiting. - Diarrhea. - Transient headache. - Local swelling.

Serious or Rare Side Effects: - Anaphylactic reaction or severe hypersensitivity. - Hemolysis or severe anemia. - Thrombosis or paradoxical clot formation. - Severe bleeding despite therapy. - Elevated liver enzymes. - Acute renal impairment.

Use with clinical judgment and monitor patients closely.

- Assess vitamin K status before initiating therapy. - Monitor coagulation parameters (PT/INR) during treatment. - Use with caution in patients with hepatic impairment. - Avoid in individuals with known hypersensitivity to phytomenadione. - Follow neonatal dosing guidelines when used for newborn prophylaxis. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Phytomenadione may alter the effect of several drugs.

Major Interactions (Avoid): - Coumarin anticoagulants (e.g., warfarin): may reduce anticoagulant effect. - Broad‑spectrum antibiotics that disrupt gut flora: can increase vitamin K deficiency risk. - Cholestyramine or other bile‑acid sequestrants: may decrease absorption of vitamin K.

Moderate Interactions (Monitor Closely): - Rifampin: may increase hepatic metabolism of vitamin K. - Phenobarbital: may enhance vitamin K clearance. - Cephalosporins: may interfere with vitamin K synthesis. - Direct oral anticoagulants: monitor coagulation status if combined.